Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 5/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9707759 | 0.94 | ADORA3 (0.44) | ADORA3ADORA2AADORA2BKMT2AADORA1 | |
| SCHEMBL9708513 | 0.94 | PDE5A (0.42) | ADORA3KMT2AAGTR1AGTR2 | |
| SCHEMBL9708000 | 0.93 | KMT2A (0.41) | ADORA3KMT2AAGTR1AGTR2 | |
| SCHEMBL9707438 | 0.93 | ADORA3 (0.49) | ADORA3ADORA2AADORA2BKMT2AADORA1 | |
| SCHEMBL9708096 | 0.92 | KMT2A (0.39) | ADORA3KMT2AAGTR1AGTR2 | |
| SCHEMBL9707343 | 0.92 | KMT2A (0.44) | KMT2AAGTR1AGTR2 | |
| SCHEMBL9707804 | 0.91 | ADORA2A (0.46) | ADORA3ADORA2AADORA2BKMT2AADORA1 | |
| SCHEMBL9707509 | 0.91 | AGTR1 (0.42) | KMT2AAGTR1AGTR2 | |
| SCHEMBL9707984 | 0.91 | KMT2A (0.39) | ADORA3KMT2AADORA1AGTR1AGTR2 | |
| SCHEMBL9707937 | 0.91 | PDE5A (0.41) | ADORA3ADORA2AKMT2AAGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1992007852-A1 | BIPHENYLALKYL XANTHINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | disclosed |